MTN-020 ASPIRE News

Archived from the MTN website before it was taken down.

MTN-020, or ASPIRE (A Study to Prevent Infection with a Ring for Extended Use), was a Phase III study to determine whether a vaginal ring containing the ARV drug dapivirine is a safe and effective method for protecting against the sexual transmission of HIV when used by women for a month at a time. ASPIRE enrolled 2,629 sexually active HIV-negative women ages 18-45 and was conducted between 2012-2015 at 15 clinical research sites in Malawi, South Africa, Uganda and Zimbabwe. Results, reported in 2016, found HIV risk was reduced by 27 percent overall and no safety concerns. HIV risk was cut by more than half (56 percent) in women older than 21, who also appeared to use the ring most consistently. Results of an exploratory analysis reported at AIDS 2016 found the level of HIV protection for those who used the ring most consistently was at least 56 percent and as high as 75 percent or more with near perfect use.

Results

• Sensitive ARV resistance tests detect no dapivirine-associated resistance among women using dapivirine vaginal ring in ASPIRE — October 24, 2018
• Researchers present additional evidence on the safety of the dapivirine vaginal ring for HIV prevention in women — October 23, 2018
• Women facing intimate partner violence were less likely to use vaginal ring in ASPIRE — October 18, 2016
• Dapivirine ring did not confer drug resistance among women who acquired HIV in ASPIRE — Oc;t 18, 2016
• HOPE open-label study of vaginal ring for preventing HIV begins for former ASPIRE participants — July 18, 2016
• Used consistently, monthly vaginal ring may be highly effective against HIV in women, suggest new analyses from ASPIRE — July 18, 2016
• Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase III trial — February 22, 2016
• ASPIRE Results At-A-Glance — February 22, 2016
• ASPIRE Q&A on Results — February 22, 2016

See Also

• Two Large Studies Show IPM’s Monthly Vaginal Ring Helps Protect Women Against HIV — February 22, 2016
• Sister Studies: The Ring Study and ASPIRE — February 22, 2016

Other Study Milestones

• Researchers complete ASPIRE Phase III trial of the dapivirine vaginal ring for HIV prevention in women; results are expected early 2016 — June 29, 2015
• ASPIRE Phase III trial of a vaginal ring for HIV prevention completes enrollment of 2,629 women — June 26, 2014
• Phase III Trial of Dapivirine Ring Begins in Africa: ASPIRE testing new HIV prevention approach for women — July 24, 2012